September 28, 2016 7:18 PM ET

Pharmaceuticals

Company Overview of Horizon Pharma plc

Company Overview

Horizon Pharma plc, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally. The company’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; DUEXIS and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis; and PENNSAID for the treatment of pain of osteoarthritis of the knees. Its products also include MIGERGOT to treat vascular headache; R...

Connaught House

1st Floor

1 Burlington Road

Dublin,  4

Ireland

Founded in 2005

915 Employees

Phone:

353 1 772 2100

Key Executives for Horizon Pharma plc

Chairman, Chief Executive Officer and President
Age: 49
Total Annual Compensation: $927.0K
Chief Financial Officer and Executive Vice President
Age: 51
Total Annual Compensation: $501.1K
Chief Operating Officer and Executive Vice President
Age: 62
Total Annual Compensation: $223.4K
Chief Business Officer and Executive Vice President
Age: 57
Total Annual Compensation: $501.1K
Executive Vice President of Global Orphan Business Unit, Primary Care and International Operations
Age: 46
Total Annual Compensation: $337.5K
Compensation as of Fiscal Year 2015.

Horizon Pharma plc Key Developments

Horizon Pharma plc, Raptor Pharmaceuticals Corp. - M&A Call

To discuss a definitive agreement to acquire all of the issued and outstanding shares of Raptor Pharmaceutical Corp. by Horizon Pharma plc

Horizon Pharma plc Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-12-2016 09:20 AM

Horizon Pharma plc Presents at The 2016 Morgan Stanley Global Healthcare Conference, Sep-12-2016 09:20 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Robert F. Carey, Chief Business Officer and Executive Vice President.

Horizon Pharma plc Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016

Horizon Pharma plc reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2016. For the quarter, the company reported net sales were $257,378,000 compared to $172,821,000 a year ago. Operating income was $31,467,000 compared to operating loss of $33,173,000 a year ago. Income before benefit for income taxes was $12,228,000 compared to loss before benefit from income taxes $128,866,000 a year ago. Net income was $14,984,000 or $0.09 diluted per share compared to $31,814,000 or $0. 20 per diluted per share a year ago. Net cash provided by operating activities was $47,303,000 compared to $41,584,000 a year ago. Purchase of property and equipment was $5,251,000 compared to $704,000 a year ago. Non-GAAP net income -prior methodology was $101,115,000 compared to $61,898,000 a year ago. Diluted adjusted Non-GAAP earnings per share -prior methodology was $0.62 against $0.39 a year ago. Non-GAAP net income was $91,264,000 compared to $58,872,000 a year ago. Diluted adjusted Non-GAAP earnings per share was $0.56 against $0.37 a year ago. EBITDA was $101,897,000 compared to LBITDA of $69,821,000 a year ago. Adjusted EBITDA was $121,080,000 compared to $76,050,000 a year ago. Non-GAAP operating cash flow was $58,186,000 compared to $129,595,000 a year ago. Second-quarter 2016 year-over-year sales growth of 49% was driven by strong execution across each of the Company’s business units: Orphan, Rheumatology and Primary Care. Medicines for rare diseases, which include RAVICTI®, ACTIMMUNE®, KRYSTEXXA® and BUPHENYL ®, represented 36% of total net sales in the second quarter of 2016, an increase from 28% of total net sales in the second quarter of 2015. For the six months, net sales were $462,068,000 compared to $285,962,000 a year ago. Operating income was $4,263,000 compared to operating loss of $28,409,000 a year ago. Loss before expense for income taxes was $34,621,000 compared to $146,506,000 a year ago. Net loss was $30,422,000 or $0.19 diluted per share compared to net income $12,261,000 or $0.08 diluted per share a year ago. Net cash provided by operating activities was $101,484,000 compared to net cash used in operating activities of $29,155,000 a year ago. Purchase of property and equipment was $12,776,000 compared to $2,281,000 a year ago. Non-GAAP net income -prior methodology was $156,557,000 compared to $86,405,000 a year ago. Diluted adjusted Non-GAAP earnings per share -prior methodology was $0.96 against $0.60 a year ago. Non-GAAP net income was $132,584,000 compared to $81,578,000 a year ago. Diluted adjusted Non-GAAP earnings per share was $0.81 against $0.56 a year ago. EBITDA was $141,747,000 compared to LBITDA of $53,034,000 a year ago. Adjusted EBITDA was $193,058,000 compared to $108,513,000 a year ago. Non-GAAP operating cash flow was $126,061,000 compared to $66,372,000 a year ago.

Similar Private Companies By Industry

Company Name Region
Adapt Pharma Europe
Bimeda Holdings PLC Europe
Carrick Therapeutics, Ltd. Europe
Celtic Catalysts Europe
Consilient Health Ltd. Europe

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
September 12, 2016
Raptor Pharmaceuticals Corp.
Buyback
May 9, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Horizon Pharma plc, please visit www.horizonpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.